Jelena Dinić

Dr. Jelena Dinić

Institute for Biological Research "Sinisa Stankovic", Belgrade, Beograd, Serbia
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
JDJelena Dinić
Jelena Dinić
PAParham Ashrafzadeh
Parham Ashrafzadeh
IPIngela Parmryd
Ingela Parmryd

8 May 2015 in Scientific Reports
Verified
Journal Article
Open access
JDJelena Dinić
Jelena Dinić
ARAstrid Riehl
Astrid Riehl
JAJeremy Adler
Jeremy Adler
IPIngela Parmryd
Ingela Parmryd
Two related models for T cell signalling initiation suggest either that T cell receptor (TCR) engagement leads to its recruitment to ordered membrane domains, often referred to as lipid rafts, where signalling molecules are enriched or that ordered TCR-containing membrane nanodomains coalesce upon TCR engagement. That ordered domains form upon TCR engagement, as they do upon lipid raft marker patching, has not been considered. The target of this study was to differentiate between those three options. Plasma membrane order was followed in live T cells at 37 degrees C using laurdan to report on lipid packing. Patching of the TCR that elicits a signalling response resulted in aggregation, not formation, of ordered plasma membrane domains in both Jurkat and primary T cells. The TCR colocalised with actin filaments at the plasma membrane in unstimulated Jurkat T cells, consistent with it being localised to ordered membrane domains. The colocalisation was most prominent in cells in G1 phase when the cells are ready to commit to proliferation. At other cell cycle phases the TCR was mainly found at perinuclear membranes. Our study suggests that the TCR resides in ordered plasma membrane domains that are linked to actin filaments and aggregate upon TCR engagement.

1 September 2020 in Drug Resistance Updates
Verified
Journal Article
Closed access
JDJelena Dinić
Jelena Dinić
Thomas EfferthThomas Efferth
Thomas Efferth
Alfonso T. Garcia-SosaAlfonso T. Garcia-Sosa
Alfonso T. Garcia-Sosa
JGJelena Grahovac
Jelena Grahovac
Jose M. PadronJose M. Padron
Jose M. Padron
ITIvanka Tsakovska
Ivanka Tsakovska

1 January 2011 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
JDJelena Dinić
Jelena Dinić
HBHenrik Biverståhl
Henrik Biverståhl
LMLena Mäler
Lena Mäler
IPIngela Parmryd
Ingela Parmryd

1 June 2010 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
SMSaleemulla Mahammad
Saleemulla Mahammad
JDJelena Dinić
Jelena Dinić
JAJeremy Adler
Jeremy Adler
IPIngela Parmryd
Ingela Parmryd

2 December 2019 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
TSTijana Stanković
Tijana Stanković
JDJelena Dinić
Jelena Dinić
Ana Podolski-RenićAna Podolski-Renić
Ana Podolski-Renić
LMLoana Musso
Loana Musso
SBSonja Stojković Burić
Sonja Stojković Burić
Milica PešićMilica Pešić
Milica Pešić
Background: Dual-targeting in cancer treatment by a single drug is an unconventional approach in relation to drug combinations. The rationale for the development of dualtargeting agents is to overcome incomplete efficacy and drug resistance frequently present when applying individual targeting agents. Consequently, -a more favorable outcome of cancer treatment is expected with dual-targeting strategies.Methods: We reviewed the literature, concentrating on the association between clinically relevant and/or novel dual inhibitors with the potential to modulate multidrug resistant phenotype of cancer cells, particularly the activity of P-glycoprotein. A balanced analysis of content was performed to emphasize the most important findings and optimize the structure of this review.Results: Two-hundred and forty-five papers were included in the review. The introductory part was interpreted by 9 papers. Tyrosine kinase inhibitors’ role in the inhibition of Pglycoprotein and chemosensitization was illustrated by 87 papers. The contribution of naturalbased compounds in overcoming multidrug resistance was reviewed using 92 papers, while specific dual inhibitors acting against microtubule assembling and/or topoisomerases were described with 55 papers. Eleven papers gave an insight into a novel and less explored approach with hybrid drugs. Their influence on P-glycoprotein and multidrug resistance was also evaluated.Conclusion: These findings bring into focus rational anticancer strategies with dual-targeting agents. Most evaluated synthetic and natural drugs showed a great potential in chemosensitization. Further steps in this direction are needed for the optimization of anticancer treatment.